AU2021107202A4 - siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION - Google Patents
siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION Download PDFInfo
- Publication number
- AU2021107202A4 AU2021107202A4 AU2021107202A AU2021107202A AU2021107202A4 AU 2021107202 A4 AU2021107202 A4 AU 2021107202A4 AU 2021107202 A AU2021107202 A AU 2021107202A AU 2021107202 A AU2021107202 A AU 2021107202A AU 2021107202 A4 AU2021107202 A4 AU 2021107202A4
- Authority
- AU
- Australia
- Prior art keywords
- dnalil
- sirna
- gene expression
- interfering
- migration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 41
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 36
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 20
- 230000002452 interceptive effect Effects 0.000 title claims abstract description 20
- 230000012292 cell migration Effects 0.000 title claims abstract description 19
- 238000013508 migration Methods 0.000 title claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 11
- 102100039409 Axonemal dynein light intermediate polypeptide 1 Human genes 0.000 title description 3
- 101001036313 Homo sapiens Axonemal dynein light intermediate polypeptide 1 Proteins 0.000 title description 3
- 230000005764 inhibitory process Effects 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 238000004925 denaturation Methods 0.000 claims description 7
- 230000036425 denaturation Effects 0.000 claims description 7
- 238000003757 reverse transcription PCR Methods 0.000 claims description 7
- 108091081021 Sense strand Proteins 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 25
- 238000011160 research Methods 0.000 abstract description 10
- 238000013461 design Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000013604 expression vector Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- 239000004055 small Interfering RNA Substances 0.000 description 22
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101150061959 Dnali1 gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000013439 flagellum movement Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Abstract
OF THE DISCLOSURE
The present disclosure provides an siRNA for interfering with DNALIl gene expression
and use thereof in inhibiting cell proliferation and migration. The present disclosure designs
and synthesizes three pairs of siRNAs for targeted inhibition of DNALIl gene expression,
which are DNALIl-siRNA-66, DNALIl-siRNA-426, and DNALIl-siRNA-777, respectively,
and expression vectors thereof in an HEK-293 cell are successfully constructed. When the
siRNA provided by the present disclosure enters a cell, the DNALIl gene expression can be
effectively and specifically interfered, and thus cell proliferation and migration are
effectively inhibited. The present disclosure fills in the blank that there is no siRNA
sequence for interfering with DNALIl gene expression; moreover, the siRNA can effectively
interfere with the expression of target gene DNALI, playing a role in treating or preventing
possible diseases caused by DNALIl gene expression, and laying a foundation for research
on the mechanism of DNALIl gene in cell proliferation and migration and future applied
research.
1.20 1.0y 0
- 1.00 0.84
o.8o 58 0 61
10.60
=3
<0.40
0.20
.0
FIG.1I
Description
siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION
[001] The present disclosure belongs to the field of molecular genetics, and particularly relates to an siRNA for interfering with DNALIl gene expression and use thereof in inhibiting cell proliferation and migration.
[002] RNA interference (RNAi) is a double-stranded RNA-mediated process of post-transcriptional silencing of a homologous target gene. RNAi can induce mRNA degradation of the endogenous target gene by artificially introducing double-stranded RNA with the same sequence as the endogenous target gene, thereby achieving the objective of reducing gene expression. The RNAi phenomenon is also a defense mechanism that is evolutionarily conservative against the transgenic or foreign virus invasion. Although the research time of RNAi technology is relatively short, the technology is an emerging gene disruption technology with high specificity, high interference efficiency, and simple operation, and is widely used in medical research on viral infection, cancer, dominant genetic diseases, and the like. Further, the technology can screen drug target genes in a high-throughput manner, and promote gene therapy and new drug development. Therefore, small interfering RNA (siRNA) is also called a "drug for treating diseases". In recent years, scientists have used RNAi technology to select specific target genes to synthesize effective siRNAs, and transform the siRNAs into specific cells by transfection, so that the siRNAs can efficiently act in host cells and silence the expression of related genes. Such means can not only analyze the function of genes in mammals at the genomic level, but also identify a plurality of genes related to diseases more quickly, so that the network system of gene regulation in organisms can be better investigated. Therefore, the RNAi technology has become the most effective means for investigating gene functions and the most attractive method for targeted gene therapy. At present, the healing function of siRNA in pathological changes in mammalian cells, organs and living bodies indicates that RNAi will be widely used in the treatment of human diseases in the near future. Therefore, the research and application of siRNA may have extremely important theoretical and practical significance, and will have a profound impact on the development of medical biology.
[003] Cell proliferation, migration, and invasion are changing processes of molecular biology that are involved in a plurality of factors and completed through a plurality of steps. Some cells with strong migration ability can make themselves overcome cell-cell and cell-matrix adhesion and invade surrounding tissues; strongly invasive cells usually reduce the cell-cell adhesion and disconnect intercellular communication by a plurality of cell synapses. Therefore, research on cell proliferation, migration, and invasion is of very great importance for diseases, cell applications, and the like.
[004] DNALI1 gene, located on chromosome 4 and composed of six exons, is mainly expressed in the testis. However, little research has been done on this gene so far. Hence, the function of this gene is not fully understood. Studies have found that the DNALIl gene may play a dynamic role in flagellar movement, and expression thereof may also be associated with recurrence following surgery for hepatocellular carcinoma. Some researchers have found lower levels of DNALIl transcript are observed in different mouse tissues (cilia and skeletal muscle). However, up to now, there has been no disclosure of siRNA sequences that interfere with DNALIl gene expression and related research or patents.
[005] An objective of the present disclosure is to provide an siRNA for interfering with DNALIl gene expression and use thereof in inhibiting cell proliferation and migration. The present disclosure designs and synthesizes three pairs of siRNAs for targeted inhibition of the expression of DNALIl gene, and successfully constructs expression vectors thereof in HEK-293 cells; meanwhile, use of these siRNAs can effectively and specifically interfere with DNALIl expression, thereby effectively inhibiting cell proliferation and migration.
[006] To achieve the above objective, the present disclosure is implemented by the following technical solutions:
[007] The present disclosure provides a DNALIl-siRNA-66 for interfering with DNALIl gene expression, where the DNALI1-siRNA-66 for interfering with DNALIl gene expression has the following nucleotide sequences:
[008] sense strand: 5'-CCGCAGACTCTTTGCTCAATT-3',
[009] antisense strand: 5'-TTGAGCAAAGAGTCTGCGGTT-3'.
[0010] The present disclosure provides a DNALIl-siRNA-426 for interfering with DNALIl gene expression, where the DNALI1-siRNA-426 for interfering with DNALIl gene expression has the following nucleotide sequences:
[0011] sense strand: 5'-GCAGGGAACTCTACTCACATT-3',
[0012] antisense strand: 5'-TGTGAGTAGAGTTCCCTGCTT-3'.
[0013] The present disclosure provides a DNALIl-siRNA-777 for interfering with DNALIl gene expression, where the DNALI1-siRNA-777 for interfering with DNALIl gene expression has the following nucleotide sequences:
[0014] sense strand: 5'-GAACAAATCAGCAGCTGAATT-3',
[0015] antisense strand: 5'-TTCAGCTGCTGATTTGTTCTT-3'.
[0016] The present disclosure further provides use of the siRNA for interfering with DNALIl gene expression in the preparation of a formulation for inhibiting cell proliferation and migration.
[0017] Further, the use may include the following steps:
[0018] step 1, transfecting the DNALIl-siRNA-66, the DNALIl-siRNA-426, or the DNALIl-siRNA-777 into a cell, and lysing to obtain total RNA;
[0019] step 2, synthesizing a first strand cDNAby reverse transcription using the total RNA in step 1 as a template;
[0020] step 3, using the cDNA in step 2 as a template, conducting RT-PCR to detect inhibition efficiency of the DNALI1-siRNA against DNALIl expression; and
[0021] step 4, transfecting DNALIl-siRNA having the highest inhibition efficiency instep 3 into a cell to prepare a formulation for inhibiting cell proliferation and migration.
[0022] Further, the DNALIl-siRNA in step 1 may have a concentration of 20 pmol.
[0023] Further, the amount of the total RNA amount in step 2 may be 10 ng to 2 g.
[0024] Further, an RT-PCR system in step 3 may be 20 d, including: 20-100 ng of a cDNA template, 1 1 of a forward primer, 1 1 of a reverse primer, and 10 [ of SuperReal PreMix. Plus, making up to 20 1 with RNase-free ddH20.
[0025] Further, an RT-PCR program in step 3 may be: initial denaturation at 95°C for 15 min; 40 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s.
[0026] Compared with the prior art, the present disclosure has the following advantages and beneficial effects:
[0027] (1) The present disclosure designs and synthesizes three pairs of siRNAs for targeted inhibition of DNALIl gene expression, which can effectively and specifically interfere with the DNALIl expression, and fills in the blank that there is no siRNA sequence for interfering with DNALIl gene expression at present.
[0028] (2) The present disclosure inhibits the cell proliferation and migration by RNAi-specific inhibition of the DNALIl gene at the cellular level, thereby inhibiting, alleviating or preventing possible diseases caused by the DNALIl gene, and laying a foundation for research on the mechanism of the DNALIl gene in cell proliferation and migration and future applied research.
[0029] FIG. 1 illustrates a 24-hour effect comparison of siRNA interference with DNALIl gene expression in different DNALI1-siRNA transfected cells of the present disclosure.
[0030] FIG. 2 illustrates a 48-hour effect comparison of siRNA interference with DNALIl gene expression in different DNALI1-siRNA transfected cells of the present disclosure.
[0031] FIG. 3 illustrates a comparison of cell proliferation ability in different DNALIl-siRNA transfected groups of the present disclosure.
[0032] FIG. 4 illustrates a comparison of cell migration ability indifferent DNALI-siRNA transfected groups of the present disclosure.
[0033] The technical solutions of the present disclosure will be further described in detail below in conjunction with specific examples.
[0034] Example 1: Design and synthesis of siRNA target sequences
[0035] The DNALIl gene sequence was obtained from GenBank. According to the siRNA design principle, three interfering target sequences were screened, designed and synthesized for the conservative region of DNALIl gene sequence, and named as DNALIl-siRNA-66, DNALIl-siRNA-426, and DNALIl-siRNA-777, respectively. At the same time, nonsense sequences that were not directed to any gene were designed to serve as a negative control (siFAM). The sequences are shown in Table 1.
[0036] Table 1 The design and synthesis of siRNA sequences Gene siRNA name Sense (5'-3') Antisense (5'-3') name DNALIll-siRNA-66 CCGCAGACTCTTTGCTCAATT TTGAGCAAAGAGTCTGCGGTT DNALIll-siRNA-426 GCAGGGAACTCTACTCACATT TGTGAGTAGAGTTCCCTGCTT DNALI1 DNALIll-siRNA-777 GAACAAATCAGCAGCTGAATT TTCAGCTGCTGATTTGTTCTT siFAM ACGTGACACGTTCGGAGAATT ACGTGACACGTTCGGAGAATT
[0037] Example 2: Cell culture and transfection
[0038] Using Dulbecco's Modified Eagle Medium (DMEM) supplemented with fetal bovine serum (FBS) and antibiotics, HEK-293 cells were cultured in a constant temperature incubator containing 5% C02 at 37°C; as the cell growth rate reached 70-90%, the cells were digested with 0.25% trypsin and passed. One day before transfection, the cells were seeded on a 24-well plate at 4-5 x 104 cells/well, and 0.5 ml of DMEM was added to each well. During transfection, 20 pmol of DNALIl-siRNA was added to 50 l of serum-free DMEM, and gently mixed well; meanwhile, 1 1 of Lipofectamin 2000 reagent was diluted with 50 [ of serum-free DMEM, gently mixed well, and allowed to stand at room temperature for 5 min. Subsequently, the diluted DNALIl-siRNAs was gently mixed well with the transfection reagent, and allowed to stand at room temperature for 20 min to form an siRNA/Lipofectamin 2000 complex. 100 1 of the complex was added to a 24-well plate containing cells, and the cell culture plate was gently shaken back and forth. The cells were incubated in a 5% C02 incubator at 37°C for 24-48 h, and the cells were collected for other detection after transfection. If the cell line is sensitive, the complex may be removed, and the medium may be changed 4-6 h after incubation.
[0039] Example 3: Detection of inhibition efficiency of siRNA
[0040] (1) Total RNA extraction
[0041] Directly, the cells were lysed by adding TRNzol reagent (11 ml/well) to the culture plate, and a sampler was used for pipetting several times; a homogenate sample was allowed to stand at 15-30°C for 5 min to completely separate a nucleic acid-protein complex. Every time 1 ml of TRNzol was consumed, 0.2 ml of chloroform was added; tube cap was covered; the tube was shaken vigorously for 15 s, allowed to stand at room temperature for 3 min, placed in a 4°C centrifuge for centrifugation at 12,000 rpm for 10-15 min. At the moment, the sample was divided into three layers: yellow organic phase, intermediate layer, and upper colorless aqueous phase; RNA was mainly in the aqueous phase, and the aqueous phase (about 600 l) was transferred to a new centrifuge tube. An equal volume of isopropanol was added to the resulting aqueous phase solution and mixed well; the mixture was allowed to stand at room temperature for 20-30 min, and centrifuged at 4°C and 12,000 rpm for 10 min to discard the supernatant. The pellets were washed with 1 ml of 75% ethanol, and centrifuged at 4°C and 5,000 rpm for 3 min to discard the supernatant. After the pellets were left to dry at room temperature, the mixture was mixed with 30-100 1 of RNase-free ddH 20, pipetted and mixed well repeatedly to sufficiently dissolve the RNA.
[0042] (2) Synthesis of first strand cDNA by reverse transcription
[0043] Template RNA was thawed on ice; 5x gDNA Buffer, FQ-RT Primer Mix, 1Ox Fast RT Buffer, and RNase-free ddH20 were thawed at room temperature, respectively, and quickly placed on ice after thawing. Before use, each solution was vortexed, mixed well, and briefly centrifuged to collect the fluid remaining on the tube wall. A mixture was prepared according to the genomic DNA removal system in Table 2, followed by thoroughly mixing. The mixture was centrifuged briefly, incubated at 42°C for 3 min, and placed on ice.
[0044] Table 2 gDNA removal reaction system Composition System 5xgDNA Buffer 2 1 Total RNA 10 ng-2 g RNase-Free ddH 20 To 10 1
[0045] The mixture was prepared according to the reverse transcription reaction system in Table 3. The mixture in the reverse transcription reaction was added to the reaction mixture in the gDNA removal step, and thoroughly mixed. After incubation at 42°C for 15 min and at °C for 3 min, cDNA was obtained and stored at low temperature.
[0046] Table 3 The reverse transcription reaction system Composition System 10x Fast RT Buffer 2 1 RT Enzyme Mix 1 FQ-RT Primer Mix 2 1 RNase-Free ddH 20 To 10 1
[0047] (3) Fluorescence quantitative PCR experiment
[0048] The reaction mixture was prepared on ice according to the RT-PCR system in Table 4, and all reagents were mixed at room temperature and thoroughly mixed.
[0049] Table 4 RT-PCR system Composition 20 1 System 2x SuperReal PreMix Plus 10 pl Forward primer (10 M) 0.6 [ Reverse primer (10 M) 0.6 1 cDNA template 20-100 ng RNase-Free ddH 20 To 20 1
[0050] The reaction system was placed in a fluorescence quantitative PCR detection system, and set up according to the RT-PCR program in Table 5 to start the reaction.
[0051] Table 5 RT-PCR program Stage Number of Temperature Time Content Fluorescence signal cycles acquisition Initial 1x 95 0 C 15 Initial No denaturation min denaturation 95 0 C 10s Denaturation No PCR 40x 600 C 30s Annealing Yes 720 C 30s Extension No Melting/Dissociation Curve Stage
[0052] The results of RT-PCR detection of siRNA interference with DNALIl gene expression are shown in FIGS. 1 to 3. The results showed that compared with the control group, the expression levels of DNALIl mRNA in three DNALIl-siRNA transfection groups were lower than those in the control group at 24 and 48 h; herein, the DNALIl gene expression level was minimized at 48 h in the DNALIl-siRNA-66 group, followed by DNALI-siRNA-777, indicating that the DNALI1-siRNA-66 had the highest interference efficiency with DNALIl gene at 48 h and the best effect.
[0053] Example 4: Cell proliferation assay
[0054] The cells transfected with DNALIl-siRNA-66 were mixed with 100 1 of cell suspension in each well of a 96-well plate, where six replicate wells were set and the cells were cultured overnight in a constant temperature incubator containing 5% C02 at 370 C; at 1-7 after culture, 10 1 of CCK8 was added to each well and the cells were incubated in the constant temperature incubator containing 5% C02 at 37 0C for 2 h; a microplate reader was used to measure the absorbance value (OD450) of each well at 450 nm; cell proliferation curves were plotted as a function of the absorbance value versus time (days).
[0055] The results of detection of cell proliferation by CCK-8 are shown in FIG. 3. Compared with the control group, the proliferation ability of the cells after silencing the DNALIl expression was gradually weakened with time, indicating that siRNA interference with DNALIl gene expression can inhibit cell proliferation ability.
[0056] Example 5: Cell migration assay
[0057] Target DNALI1-siRNA-66 transfected cells effectively interfered by siRNA and control cells were selected for culture; cells transfected with DNALIl-siRNA in log phase were routinely digested and centrifuged, the supernatant was discarded, the cells were suspended with serum-free DMEM to prepare a single cell suspension, and the density was adjust to 5 x 105 cells/ml. 200 1 of the cell suspension was added to the upper layer of each Transwell chamber, and 700 1 of DMEM supplemented with 10% FBS was added along the inner wall of the lower layer to avoid bubbling; incubation was carried out in a constant temperature incubator containing 5% C02 at 37°C for 16 h. The Transwell chambers were removed, the cells were carefully wiped off the upper surface of the chamber filter membrane with a cotton swab; the chamber was fixed in methanol for 15 min, washed with PBS thrice to remove residual methanol, and stained in 0.2% crystal violet stain for 20 min, and washed thrice with PBS to remove excess stain, and the cells were observed and photographed under a microscope.
[0058] The results of the cell migration observed by the Transwell migration assay are shown in FIG. 4. Compared with the control group, the migration ability of the cells after the siRNA interference with the DNALIl gene expression was weakened.
[0059] The above examples are only intended to illustrate, but not to limit, the technical solutions of the present disclosure; although the present disclosure has been described in detail with reference to the foregoing examples, for those of ordinary skill in the art, the technical solutions of the foregoing examples may still be modified, or some of the technical features may be equivalently substituted; these modifications or substitutions do not cause the essence of the corresponding technical solutions to depart from the spirit and scope of the technical solutions claimed by the present disclosure.
Claims (5)
1. Use of an siRNA for interfering with DNALIl gene expression in the preparation of a formulation for inhibiting cell proliferation and migration, wherein the cell is an HEK-293 cell; the siRNA for interfering with DNALIl gene expression is DNALIl-siRNA-66, DNALI1-siRNA-426, or DNALI-siRNA-777; the DNALIl-siRNA-66 for interfering with DNALIl gene expression has the following target sequences: sense strand: 5'-CCGCAGACTCTTTGCTCAATT-3', antisense strand: 5'-TTGAGCAAAGAGTCTGCGGTT-3'; the DNALIl-siRNA-426 for interfering with DNALIl gene expression has the following target sequences: sense strand: 5'-GCAGGGAACTCTACTCACATT-3', antisense strand: 5'-TGTGAGTAGAGTTCCCTGCTT-3'; the DNALIl-siRNA-777 for interfering with DNALIl gene expression has the following target sequences: sense strand: 5'-GAACAAATCAGCAGCTGAATT-3', antisense strand: 5'-TTCAGCTGCTGATTTGTTCTT-3'; and the use specifically comprises the following steps: step 1, transfecting the DNALIl-siRNA-66, the DNALIl-siRNA-426, or the DNALIl-siRNA-777 into a cell, and lysing to obtain total RNA; step 2, synthesizing a first strand cDNA by reverse transcription using the total RNA in step 1 as a template; step 3, using the cDNA in step 2 as a template, conducting RT-PCR to detect inhibition efficiency of the DNALIl-siRNA against DNALIl expression; and step 4, transfecting DNALIl-siRNA having the highest inhibition efficiency in step 3 into a cell to prepare a formulation for inhibiting cell proliferation and migration.
2. The use according to claim 1, wherein the DNALIl-siRNA in step 1 has a concentration of 20 pmol.
3. The use according to claim 1, wherein the amount of the total RNA in step 2 is 10 ng to 2 g.
4. The use according to claim 1, wherein an RT-PCR system in step 3 is 20 d, comprising: 20-100 ng of a cDNA template, 1 1 of a forward primer, 1 1 of a reverse
1.3
primer, and 10 1 of SuperReal PreMix. Plus, making up to 20 1 with RNase-free ddH20.
5. The use according to claim 1, wherein an RT-PCR program in step 3 is: initial denaturation at 95°C for 15 min; 40 cycles of denaturation at 95°C for 10 s, annealing at °C for 30 s, and extension at 72°C for 30 s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021107202A AU2021107202A4 (en) | 2021-08-25 | 2021-08-25 | siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021107202A AU2021107202A4 (en) | 2021-08-25 | 2021-08-25 | siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021107202A4 true AU2021107202A4 (en) | 2021-12-09 |
Family
ID=78819160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021107202A Ceased AU2021107202A4 (en) | 2021-08-25 | 2021-08-25 | siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021107202A4 (en) |
-
2021
- 2021-08-25 AU AU2021107202A patent/AU2021107202A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis | |
| Guo et al. | MiR-125a TNF receptor-associated factor 6 to inhibit osteoclastogenesis | |
| EP2240582B1 (en) | Positive controls for expression modulating experiments | |
| CN113186306A (en) | miRNA related to skin hair follicle maturation of sheep and application thereof | |
| AU2021107202A4 (en) | siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION | |
| CN104031916B (en) | New RNAi precursors and its preparation and application | |
| LU501549B1 (en) | siRNA FOR INTERFERING WITH DNALI1 GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION | |
| CN109745335B (en) | Application of miR-218 in preparation of breast cancer chemotherapeutic drug sensitizer | |
| CN109486816B (en) | Polynucleotide for treating tumor and its application | |
| CN107625780B (en) | Non-small cell lung cancer diagnosis marker microRNA-1253 and application thereof in medicine and diagnosis kit | |
| Li et al. | MicroRNA-486–3p promotes the proliferation and metastasis of cutaneous squamous cell carcinoma by suppressing flotillin-2 | |
| CN115666590B (en) | Oral squamous carcinoma related biomarker and diagnostic and therapeutic methods | |
| LU501763B1 (en) | SMALL INTERFERING RNAs (siRNAs) FOR INTERFERING WITH ZINC FINGER PROTEIN 24 (ZNF24) GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION | |
| CN111575381A (en) | Novel use of biomarkers | |
| CN111560437A (en) | Biomarkers for predicting oral squamous carcinoma and their use in therapy | |
| CN107881237B (en) | Lung cancer diagnosis marker microRNA-4317 and application thereof in medicines and diagnosis kit | |
| CN107184983B (en) | Diagnosis and treatment target for lung adenocarcinoma | |
| EP4023229A1 (en) | Sirna capable of inhibiting expression of mcm7 gene, composition, and application thereof | |
| CN113832155B (en) | Liver cancer-related tumor marker and application thereof | |
| CN111321226B (en) | Application of nucleic acid for detecting or inhibiting LncRNA PPP1R14B-AS1 | |
| CN113789340B (en) | Expression vector of circular RNA hsa_circ_0001741, recombinant engineering bacterium and application thereof | |
| CN116286828B (en) | Oligonucleotide siRNA and application thereof in preparation of drugs for preventing and treating liver cancer | |
| CN111560376B (en) | siRNA for specifically inhibiting OLFM4 gene expression and application thereof | |
| CN112941183B (en) | Application of non-coding gene miR-187-5p in primary liver cancer diagnosis and treatment | |
| CN108384856B (en) | Non-coding RNA for regulating and controlling expression of C4B gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |